Back to Authors

Shrestha, Raslina

0009-0007-0246-0667

A5134536048 | I1330342723

Mayo Clinic

Mayo Clinic

Citations 5

Differential survival with adjuvant immunotherapy in stage III acral versus non‐acral melanoma

Journal of the European Academy of Dermatology and Venereology | June 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/jdv.70567 | PMID 42378040

Study of Metformin and GLP-1 Receptor Agonist Use in Hidradenitis Suppurativa Using the NIH All of Us Research Program

Diabetes Care | June 12, 2026 | Volume: 49 | Issue: 8 | Pages: e138-e139

10.2337/dc26-0165 | PMID 42283704

Drug-Associated Pyogenic Granuloma: Insights from Multinational Pharmacovigilance Data

Journal of Cutaneous Medicine and Surgery | May 27, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/12034754261453367 | PMID 42200315

Drug Survival of Adalimumab and Infliximab in Hidradenitis Suppurativa

International Journal of Dermatology | May 14, 2026 | Volume: 65 | Issue: 9 | Pages: 1907-1909

10.1111/ijd.70455 | PMID 42129594

Vitamin D deficiency and systemic inflammation in hidradenitis suppurativa: clinical correlates in a retrospective cohort

British Journal of Dermatology | April 30, 2026 | Volume: 195 | Issue: 2 | Pages: 339-341

10.1093/bjd/ljag157 | PMID 42056003

Vitamin D deficiency is frequently reported in hidradenitis suppurativa (HS), but its clinical significance remains unclear. In a retrospective cohort of 503 patients, deficiency was common and associated with demographic and metabolic factors but not with treatment-defined severity. Vitamin D deficiency was independently associated with elevated C-reactive protein, suggesting a link with systemic inflammation.